[
  {
    "ts": null,
    "headline": "Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates",
    "summary": "MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.",
    "url": "https://finnhub.io/api/news?id=04de3c58bb15a4e1acf0fe001236a6c7319e125fa53efd9e762ecc7f1397ee58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771000680,
      "headline": "Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates",
      "id": 139086574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.",
      "url": "https://finnhub.io/api/news?id=04de3c58bb15a4e1acf0fe001236a6c7319e125fa53efd9e762ecc7f1397ee58"
    }
  },
  {
    "ts": null,
    "headline": "MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?",
    "summary": "Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.",
    "url": "https://finnhub.io/api/news?id=e742416bb08832e7c5795120778667ed2a078de67e6b9914864006e727f50d7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770997740,
      "headline": "MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?",
      "id": 139086575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.",
      "url": "https://finnhub.io/api/news?id=e742416bb08832e7c5795120778667ed2a078de67e6b9914864006e727f50d7b"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
    "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
    "url": "https://finnhub.io/api/news?id=21b1175e98601e8fccff0817bdbff0d4f773ab6e18677644b7a5686c6ff41f0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770996900,
      "headline": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
      "id": 139084994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
      "url": "https://finnhub.io/api/news?id=21b1175e98601e8fccff0817bdbff0d4f773ab6e18677644b7a5686c6ff41f0a"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+, as determined by an FDA-authorized test, […]",
    "url": "https://finnhub.io/api/news?id=3be8d972b2ff8321b1150de338560c4612f0cf6af1aee767d020e71606ff7ad5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994653,
      "headline": "Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+",
      "id": 139085045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+, as determined by an FDA-authorized test, […]",
      "url": "https://finnhub.io/api/news?id=3be8d972b2ff8321b1150de338560c4612f0cf6af1aee767d020e71606ff7ad5"
    }
  },
  {
    "ts": null,
    "headline": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
    "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
    "url": "https://finnhub.io/api/news?id=b1cffd6bc7d8cb84cb1a97c112ea52c9bda8409ed17002e316d6bd1889d92b41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770993360,
      "headline": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
      "id": 139085046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
      "url": "https://finnhub.io/api/news?id=b1cffd6bc7d8cb84cb1a97c112ea52c9bda8409ed17002e316d6bd1889d92b41"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=b8100201078c2d1027caddfe5a0e1e9e0b48028ff432f3e7f622db4b9f5952d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770993005,
      "headline": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?",
      "id": 139085047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=b8100201078c2d1027caddfe5a0e1e9e0b48028ff432f3e7f622db4b9f5952d2"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=e3e462297ccce2cb2fcc19e843192f6e6cdcb248c7c6024f13c96d4b9075bf4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770991205,
      "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
      "id": 139085048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=e3e462297ccce2cb2fcc19e843192f6e6cdcb248c7c6024f13c96d4b9075bf4b"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr",
    "url": "https://finnhub.io/api/news?id=f3a6a8af1e914a386c5bdd68b31b3e606c997028e0f38a0953b07959efb8e9b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770991167,
      "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report",
      "id": 139081972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr",
      "url": "https://finnhub.io/api/news?id=f3a6a8af1e914a386c5bdd68b31b3e606c997028e0f38a0953b07959efb8e9b6"
    }
  },
  {
    "ts": null,
    "headline": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
    "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
    "url": "https://finnhub.io/api/news?id=b10722ec632a4ca5c9281c2f36b849957bc9cec7f6d6344db2e46cf5b0070504",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770987636,
      "headline": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
      "id": 139081170,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
      "url": "https://finnhub.io/api/news?id=b10722ec632a4ca5c9281c2f36b849957bc9cec7f6d6344db2e46cf5b0070504"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-China biotech licensing boom to hit record in 2026 as pipeline swells",
    "summary": "By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent",
    "url": "https://finnhub.io/api/news?id=1212882825171c00f80f05825bc36312bb34ba36037ef4ff401d09d06ce7b99a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770975137,
      "headline": "Analysis-China biotech licensing boom to hit record in 2026 as pipeline swells",
      "id": 139079148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent",
      "url": "https://finnhub.io/api/news?id=1212882825171c00f80f05825bc36312bb34ba36037ef4ff401d09d06ce7b99a"
    }
  },
  {
    "ts": null,
    "headline": "3 Mega-Cap Stocks for Long-Term Investors",
    "summary": "\"Too big to fail\" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.",
    "url": "https://finnhub.io/api/news?id=c7ed1b96f743d54ffaf76e90b020ad0f851857c49e59a8ecffc754c9131bb2e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770957183,
      "headline": "3 Mega-Cap Stocks for Long-Term Investors",
      "id": 139089661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "\"Too big to fail\" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.",
      "url": "https://finnhub.io/api/news?id=c7ed1b96f743d54ffaf76e90b020ad0f851857c49e59a8ecffc754c9131bb2e3"
    }
  }
]